Vistagen Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2012, compared with fiscal 2011. Although the request metadata refers to “2011 Q4,” this filing is an annual report for fiscal 2012; it also presents unaudited quarterly results. The May 2011 reverse merger and recapitalization affect comparability of share and per-share figures.
Business context and reporting period
Vistagen is a development-stage biotechnology company applying human pluripotent stem cell technology to drug rescue and cell therapy. Its programs include CardioSafe 3D heart-toxicity screening, development of LiverSafe 3D liver assays, and AV-101, an oral prodrug in Phase 1b development for neuropathic pain. The company had no product-sales revenue; reported revenue principally came from government grants.
Key financial metrics
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $1.342 million | $2.071 million |
| Research and development expense | $5.389 million | $3.678 million |
| General and administrative expense | $4.997 million | $4.958 million |
| Operating loss | $9.043 million | $6.565 million |
| Net loss | $12.210 million | $9.482 million |
| Basic and diluted loss per share | $0.83 | $1.81 |
| Cash used in operating activities | $3.566 million | $0.841 million |
Revenue was entirely grant revenue in both years. The filing reports net loss margins of approximately -910% of revenue and operating loss margins of approximately -674% for FY2012, reflecting the very small revenue base relative to development and corporate costs. Interest expense was $1.893 million; FY2012 also included a $1.194 million loss on early extinguishment of debt.
At March 31, 2012, cash and cash equivalents were $81,000, total current assets $238,100, current liabilities $3.182 million, total liabilities $6.047 million, and stockholders’ deficit $5.706 million. The filing states that current liabilities exceeded current assets by about $2.9 million. Future minimum principal payments on long-term debt were reported at $4.281 million; capital lease obligations totaled approximately $20,200.
Financing cash inflow of $3.540 million largely offset operating and investing cash use. Cash declined by $58,300 from the prior year-end. The company reported an accumulated deficit of $54.783 million.
Material changes versus FY2011
- Revenue fell about 35%, mainly as the AV-101 NIH grant approached completion and the CIRM liver-research grant ended in September 2011.
- R&D expense rose about 46%, to $5.389 million, driven principally by AV-101 third-party development costs, personnel, and stem-cell research and licensing activity.
- G&A expense was nearly unchanged at $4.997 million, but its composition shifted: FY2011 included substantial costs for a contemplated Toronto Stock Exchange listing, while FY2012 included public-company, consulting, investor-relations, and warrant-modification costs.
- Net loss increased about 29%. Interest expense declined from $3.119 million, but the FY2012 debt-extinguishment loss and higher operating loss more than offset that reduction.
- The May 2011 reverse merger converted substantial prior debt and preferred stock into equity. In December 2011, Platinum’s $4 million note and warrants were exchanged for Series A preferred shares; the transaction generated the reported debt-extinguishment loss.
Outlook, risks, contingencies, and unusual items
- Liquidity and going concern: Management estimated cash expenditures of $4 million to $6 million over the next 12 months and said available cash and subsequent funding would not fund operations through that period. The auditor’s report expressed substantial doubt about the company’s ability to continue as a going concern. Additional capital was not committed, and financing could be dilutive or unavailable.
- Subsequent financing: After year-end, warrant exercises generated approximately $269,800 in cash proceeds and service-payment offsets. The company also agreed to issue Platinum $500,000 of secured, 10% convertible notes in July 2012. These transactions do not eliminate the stated funding risk.
- Program outlook: Management expected to complete AV-101 Phase I clinical development in calendar 2012 and planned to begin heart-focused drug-rescue programs in 2012. The filing provides no quantified revenue or earnings guidance. CardioSafe’s supporting validation study was internal and had not undergone peer review or third-party validation; mature functional liver cells and LiverSafe 3D remained under development.
- Grant concentration: The AV-101 NIH grant represented 87% of FY2012 revenue and was scheduled to end June 30, 2012; the CIRM grant had ended in September 2011. Replacement funding was uncertain.
- Debt and obligations: The company had significant payables and notes, and disclosed missed scheduled payments on certain notes. It also had contractual research and license commitments, including monthly UHN research payments through September 2012 and potential milestone payments under UHN licenses.
- Other risks: The company had never developed a drug-rescue variant and depended on unvalidated assay performance, collaborators, intellectual-property rights, regulatory approvals, and additional financing. Its stock traded on the OTC Bulletin Board, with limited liquidity and material dilution potential from outstanding options, warrants, and convertible securities.
- Unusual non-cash items: FY2012 expenses included warrant modifications and stock- or warrant-based compensation; the Platinum exchange produced a debt-extinguishment charge. The company reported no ongoing material legal proceedings.
Important facts for investors to verify
- Cash runway and actual post-filing financing received, including the terms and security of the July 2012 Platinum notes and any required follow-on financing.
- Current debt, overdue payments, accounts payable, and the timing and source of funds needed to meet the $4 million to $6 million expenditure estimate.
- Whether AV-101 Phase I development was completed as planned, and the resulting clinical data, grant support, and next development decisions.
- Independent reproducibility and predictive performance of CardioSafe 3D, progress toward mature liver cells and LiverSafe 3D, and whether any drug-rescue candidate or pharmaceutical collaboration has advanced.
- Fully diluted share count and potential dilution from preferred-stock conversion, options, warrants, and convertible notes. The filing reports 16,620,409 common shares outstanding at March 31, 2012, but gives different later share counts in separate sections; reconcile these with the reported June 2012 figures.
- Grant concentration and replacement funding after the NIH and CIRM awards ended or approached completion, as well as the company’s ability to achieve revenue beyond grants.